Colorectal cancer (CRC) is one of the most common and deadliest forms of cancer worldwide. Molecular subgroups are increasingly relevant for prognosis and therapy. In addition to established markers such as RAS, BRAF and MSI, HER2 is also coming into focus as a therapeutic target. Particularly rare histological variants such as invasive micropapillary carcinoma (IMPC) raise new questions. A recent case report from Japan describes for the first time a patient with HER2-positive colorectal carcinoma and a micropapillary component. This article summarizes the available data and discusses the clinical significance of this constellation.
Autoren
- Tanja Schliebe
Publikation
- InFo ONKOLOGIE & HÄMATOLOGIE
Related Topics
You May Also Like
- Brain atrophy and MS
Brain atrophy correlates with disability progression in MS
- Diabetes mellitus
Treatment of comorbidities in older people
- Alternative to insulin and GLP1
From the β-cell to the center: the versatile role of amylin
- Pulmonary sarcoidosis
Prednisone vs. MTX: a draw after 24 weeks
- Friedreich's ataxia
Loss of orientation in the cerebellum
- Diabetes mellitus
Treatment of comorbidities in older people
- Artificial intelligence
Dr. ChatGPT: Large language models in everyday clinical practice
- Subtyping as the key to precision medicine